Regnum Corp. (RGMP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 772.6 Thousand USD | 3402.3% |
| 2021 | 22.06 Thousand USD | 0.0% |
| 2020 | - USD | 100.0% |
| 2019 | -7444.00 USD | 84.26% |
| 2018 | -47.29 Thousand USD | -225.05% |
| 2017 | -14.55 Thousand USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 1.1 Million USD | 42.92% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q4 | 772.6 Thousand USD | 22.37% |
| 2022 FY | 772.6 Thousand USD | 3402.3% |
| 2022 Q2 | 269.66 Thousand USD | 122.0% |
| 2022 Q1 | 121.46 Thousand USD | 450.63% |
| 2022 Q3 | 631.38 Thousand USD | 134.14% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q4 | 22.06 Thousand USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | 22.06 Thousand USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | - USD | 100.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 100.0% |
| 2020 Q2 | - USD | 0.0% |
| 2019 FY | -7444.00 USD | 84.26% |
| 2019 Q1 | -20.33 Thousand USD | 57.01% |
| 2019 Q4 | -7444.00 USD | 44.12% |
| 2019 Q3 | -13.32 Thousand USD | -1.95% |
| 2019 Q2 | -13.06 Thousand USD | 35.74% |
| 2018 Q1 | -16.39 Thousand USD | -12.66% |
| 2018 FY | -47.29 Thousand USD | -225.05% |
| 2018 Q4 | -47.29 Thousand USD | -0.28% |
| 2018 Q3 | -47.16 Thousand USD | -172.63% |
| 2018 Q2 | -17.29 Thousand USD | -5.53% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | -14.07 Thousand USD | 0.0% |
| 2017 Q4 | -14.55 Thousand USD | -3.37% |
| 2017 FY | -14.55 Thousand USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 59077.634% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 86.322% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 98.195% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 409.513% |
| Rebus Holdings, Inc. | 305 Thousand USD | -153.314% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 112.255% |
| Qrons Inc. | 351.42 Thousand USD | -119.849% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -24.141% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 98.221% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 3885.805% |
| Skye Bioscience, Inc. | -5.72 Million USD | 113.504% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 95.099% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 81.238% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -92.263% |
| SQZ Biotechnologies Company | -36.23 Million USD | 102.132% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 65.543% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 16.672% |
| Mesoblast Limited | 55.85 Million USD | 98.617% |
| Marizyme, Inc. | 18.56 Million USD | 95.839% |
| Genus plc | 190.6 Million USD | 99.595% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 65.444% |
| Pharming Group N.V. | 109.8 Million USD | 99.296% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 10.187% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 36.353% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -13.619% |
| ContraFect Corporation | -6.02 Million USD | 112.821% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -473.836% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 33.132% |
| IMV Inc. | 7.67 Million USD | 89.928% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 85.957% |
| MultiCell Technologies, Inc. | 90.04 USD | -857970.857% |
| ONE Bio Corp. | 9.04 Million USD | 91.453% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 205.263% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 94.032% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 43.522% |
| Q BioMed Inc. | 4.06 Million USD | 80.97% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 97.471% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 23.331% |
| Biomind Labs Inc. | 711.4 Thousand USD | -8.603% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.724% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 61.358% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 93.967% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -114.786% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -452.636% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -3788.896% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 64.913% |
| GB Sciences, Inc. | 1.74 Million USD | 55.783% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 520.379% |
| HST Global, Inc. | 96.79 Thousand USD | -698.205% |
| CSL Limited | 10.52 Billion USD | 99.993% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -274.657% |
| Halberd Corporation | 144.72 Thousand USD | -433.86% |
| Enzolytics Inc. | 981.65 Thousand USD | 21.296% |
| Agentix Corp. | 37.63 Thousand USD | -1953.113% |
| Resverlogix Corp. | 6.45 Million USD | 88.023% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 214.785% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.038% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 101.643% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 89.074% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 71.476% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 108.74% |
| AVAX Technologies, Inc. | -5.9 Million USD | 113.088% |
| Zenith Capital Corp. | 10.06 Thousand USD | -7576.938% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.073% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -285.471% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 67.62% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -369.644% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 4317.748% |
| Kadimastem Ltd | -253.1 Thousand USD | 405.255% |
| Helix BioMedix, Inc. | -2.57 Million USD | 130.062% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 96.19% |
| BioStem Technologies, Inc. | 4.47 Million USD | 82.723% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -283.896% |
| LadRx Corporation | -2.03 Million USD | 137.939% |
| Cell Source, Inc. | 9.23 Million USD | 91.631% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -21.638% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -21.638% |
| NovAccess Global Inc. | 2.17 Million USD | 64.534% |
| Affymax, Inc. | -5.59 Million USD | 113.804% |
| Itoco Inc. | 228.3 Thousand USD | -238.41% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -468.139% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 84.414% |
| Mobile Lads Corp. | 484.23 Thousand USD | -59.553% |
| CytoDyn Inc. | 20.26 Million USD | 96.187% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 119513.756% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 8435.98% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 89.974% |
| SYBLEU INC | 473.71 Thousand USD | -63.096% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 82.665% |
| International Stem Cell Corporation | 2.59 Million USD | 70.17% |
| Bioxytran, Inc. | 1.89 Million USD | 59.313% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1137.894% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 64.574% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 77.501% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 90.967% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 161.809% |
| Neutra Corp. | 52.18 Thousand USD | -1380.459% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 131.041% |
| PureTech Health plc | -167.19 Million USD | 100.462% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 415.468% |
| IXICO plc | -4.44 Million USD | 117.383% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 94.155% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 98.591% |
| CSL Limited | 10.52 Billion USD | 99.993% |
| Cellectis S.A. | -43.81 Million USD | 101.763% |